Acumen Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
13/05/2025 14:31
Acumen Pharmaceuticals Inc ABOS.OQ reported a quarterly adjusted loss of 48 cents per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of six analysts for the quarter was for a loss of 45 cents per share. Wall Street expected results to range from -57 cents to -21 cents per share. Reported revenue was zero; analysts expected zero. Acumen Pharmaceuticals Inc's reported EPS for the quarter was a loss of 48 cents. The company reported a quarterly loss of $28.8 million. Acumen Pharmaceuticals Inc shares had fallen by 4.5% this quarter and lost 39.0% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 2.4% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy." Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $10.00 This summary was machine generated from LSEG data May 13 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.45 | -0.48 | Missed |
| Dec. 31 2024 | -0.48 | -0.62 | Missed |
| Sep. 30 2024 | -0.36 | -0.50 | Missed |
| Jun. 30 2024 | -0.28 | -0.34 | Missed |